AM, Hopkins MT, Weston PJ, et al: Effects of GH replacement on 24 h ambulatory blood pressure and its circardian rhythm in adult GH deficiency. Clin Endocrinol 2002;56:431–437.
55Sverrisdottir YB, Elam M, Herlitz H, et al: Intense sympathetic nervous system activity in adults with hypopituitarism and untreated growth hormone deficiency. J Clin Endocrinol Metab 1998;83:1881–1885.
56Savanelli MC, Scarano E, Muscogiuri G, Barrea L, Vuolo L, Rubino M, Savastano S, Colao A, Di Somma C: Cardiovascular risk in adult hypopituitaric patients with growth hormone deficiency: is there a role for vitamin D? Endocrine 2016;52:111–119.
57Forman JP, Williams JS, Fisher ND: Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans. Hypertension 2010;55:1283–1288.
58Evans LM, Davies JS, Goodfellow J, et al: Endothelial dysfunction in hypopituitary adults with growth hormone deficiency. Clin Endocrinol 1999;50:457–464.
59Krzyzanowska K, Mittermayer F, Schanck C, Hofer M, Woltz M, Schernthaner G: Circulating ADMA concentrations are elevated in hypopituitary adults with and without growth hormone deficiency. Eur J Clin Invest 2005;3593:208–213.
60Setola E, Monti LD, Lanzi R, et al: Effects of growth hormone treatment on arginine to asymmetric dimethylarginine ratio and endothelial function in patients with growth hormone deficiency. Metabolism 2008;57:1685–1690.
61Pfeifer M, Verhoves R, Zizek B, et al: Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J Clin Endocrinol Metab 1999;50:453–457.
62Kvasnicka J, Marek J, Kvasnicka T, et al: Increase of adhesion molecules, fibrinogen, type-1 plasminogen activator inhibitor and orosomucoid in growth hormone deficient adults and their modulation by recombinant human GH replacement. Clin Endocrinol (Oxf) 2000;52:543–548.
63Sartorio A, Cattaneo M, Bucciarelli P, et al: Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly. Exp Clin Endocrinol Diabetes 2000;108:486–492.
64Sesmilo G, Biller BM, Lievadot J, Hayden D, Hanson G, Rifai N, Klibanski A: Effects of growth hormone administration on inflammation and other cardiovascular risk markers in men with growth hormone deficiency, a randomized, controlled, clinical trial. Ann Intern Med 2000;133:111–122.
65Sesmilo G, Biller BM, Lievadot J, Hayden D, Hanson G, Rifai N, Klibanski A: Effects of growth hormone (GH) administration on homocysteine levels in men with GH deficiency: a randomized controlled trial. J Clin Endocrinol Metab 2001;86:1518–1524.
66Johansson JO, Landin K, Johansson G, Tengborn L, Bengtsson BA: Long treatment with growth hormone decreases plasminogen activator inhibitor and tissue plasminogen activator in growth hormone deficient adults. Thromb Haemost 1996;76:422–428.
67Devin JK, Blevins LS, Verity DK, Chen Q, Bloodworth JR, Covington J, Vaughan DE: Markedly impaired fibrinolytic balance contributes to cardiovascular risk in adults with growth hormone deficiency. J Clin Endocrinol Metab 2007;92:3633–3639.
68Di Minno MN, Palmieri V, Lombardi G, Pezzulo S, Cirillo F, Di Somma C, Valle D, Di Minno G: Lack of change in insulin levels as a biological marker of PAI-1 lowering in GH-deficient adults on r-HGH replacement therapy. Thromb Res 2009;124:711–713.
69Miljic D, Miljic P, Doknic M, Pekic S, M Stojanovic, Cvijovic G, Micic D, Popovic V: Growth hormone replacement normalizes impaired fibrinolysis: new insights into endothelial dysfunction in patients with hypopituitarism and growth hormone deficiency. Growth Horm IGF Res 2013;23:243–248.
70Mc Callum RW, Sainsbury CA, Spiers A, et al: Growth hormone replacement induces decrease of C-reactive protein and large artery stiffness but does not alter endothelial function in patients with adult growth hormone deficiency. Clin Endocrinol 2005;62:473–479.
71Bollerslev J, Ueland T, Jørgenssen AP, et al: Positive effects of a physiological dose of GH on markers of atherogenesis: a placebo-controlled study in patients with adult-onset GH deficiency. Eur J Endocrinol 2006;154:537–543.
72Colao A, Marzullo C, Di Somma C, Lombardi G: Growth hormone and the heart. Clin Endocrinol 2001;54:137–154.
73Widdowson WM, Gibney J: The effect of growth hormone replacement on exercise capacity in patients with GH deficiency: a meta-analysis. J Clin Endocrinol Metab 2008;93:4413–4417.
74Nass R, Huber RM, Klauss V, Muller OA, Schopohl J, Strasbubrger CJ: Effect of growth hormone (hGH) replacement therapy on physical work capacity and cardiac and plumonary function in patients with GH deficiency acquired in adulthood. J Clin Endocrinol Metab 1995;80:552–557.
75Cenci MC, Soares DV, Spina LD, de Lima Oliviera Brasil RR, Lobo PM, Mansur VA, Gold J, Michmacher E, Vaisman M, Conceicao FL: Effects of 5 years of growth hormone (GH) replacement therapy on cardiac parameters and physical performance in adults with GH deficiency. Pituitary 2009;12:322–329.
76Thomas JD, Dattani A, Zemrak F, Burchell T, Akker SA, Gurnell M, Grossman AB, Davies LC, Korbonits M: Characterization of myocardial structure and function in adult- onset growth hormone deficiency using cardiac magnetic resonance. Endocrine 2016;54:778–787.
77Elgzyri T, Castenfors J, Hagg E, Backman C, Thoren M, Bramnert M: The effects of GH replacement therapy on cardiac morphology and function, exercise capacity and serum lipids in elderly patients with GH deficiency. Clin Endocrinol 2004;61:113–122.
78Andersson M, Faber J, Kjaer A, Petersen CL, Kristiansen LO: Cardiac function in growth hormone deficient patients before and after 1 year with replacement therapy: a magnetic resonance imaging study. Pituitary 2011;14:1–10.
79Klose M, Jonsson B, Abs R, Popovic V, Koltowska-Häggström M, Saller B, Feldt-Rasmunssen U, Kourides I: From isolated GH deficiency to multiple pituitary hormone deficiencies: an evolving continuum – a KIMS analysis. Eur J Endocrinol 2009;161:S75–S83.
80Melmed S: Idiopathic adult growth hormone deficiency. J Clin Endocrinol Metab 2013;98:2187–2197.
